CAR T-Cell Therapy Research Updates | Dana-Farber Cancer Institute
CAR T-cell therapy is a powerful addition to cancer immunotherapy and has offered new hope to patients with certain blood cancers so far.
CAR T-cell therapy is a powerful addition to cancer immunotherapy and has offered new hope to patients with certain blood cancers so far.
2023 Featured Articles July 13 – Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial Citation: van Hemert,…
An abstract is unavailable.
Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer.
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick…
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.
MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.
A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Montgomery Cancer Center, Prattville Campus,…
The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.
Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.